Trelegy Ellipta is indicated for maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long-acting ß2-agonist (LABA) or a combination of a long-acting ß2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA).
The recommended and maximum dose of Trelegy Ellipta (92/55/22 mcg) is one inhalation once a day. If a dose is missed the next dose should be taken at the usual time the next day. No dose adjustments are required for special populations.1
In the IMPACT trial, Trelegy Ellipta demonstrated superior improvement in lung function vs. Relvar Ellipta (fluticasone furoate/vilanterol) 92/22mcg at 52 weeks1
In the FULFIL study, Trelegy Ellipta demonstrated superior improvement in lung function vs. Symbicort Turbohaler (budesonide/formoterol) 320/9mcg at 24 weeks1
In the IMPACT trial, Trelegy Ellipta demonstrated superior reduction in the rate of exacerbations vs. Relvar Ellipta (fluticasone furoate/vilanterol) 92/22mcg over 52 weeks (Primary Endpoint)1
In the FULFIL study, Trelegy Ellipta demonstrated significant reduction in the annual rate of exacerbations vs. Symbicort Turbohaler (budesonide/formoterol) 320/9mcg over 24 weeks1
With Ellipta, significantly fewer patients with COPD made critical errors* compared to other commonly used inhalers after reading the patient information leaflet (p<0.001 for all comparisons)1-3
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
Trelegy and Ellipta are registered trademarks of the GlaxoSmithKline group of companies
PM-GB-FVU-WCNT-190003 (V 2.0) Last updated: November 2019